Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (71-80 of 150) with videos related to

Pageof 15
Sort By:
Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.
Iscience|January 8, 2024
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIVMatteo Augello, Valeria Bono, Roberta Rovito, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2017
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIVAndrea De Luca, Patrizia Lorenzini, Antonella Castagna, et al.
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2020
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patientsFrancesco Saladini, Alessia Giannini, Federica Giammarino, et al.
BMC Infectious Diseases|March 8, 2017
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyElena Raffetti, Francesco Donato, Salvatore Casari, et al.
The Journal of Antimicrobial Chemotherapy|December 23, 2019
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
The Lancet. HIV|October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trialFranco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Open Forum Infectious Diseases|May 22, 2026
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA CohortAlessandra Vergori, Adriana Cervo, Ashley Roen, et al.
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
Pageof 15

Showing results (71-80 of 150) with videos related to

Sort By:
Pageof 15
Plos One|June 28, 2016
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Franco Maggiolo, et al.
Iscience|January 8, 2024
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIVMatteo Augello, Valeria Bono, Roberta Rovito, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2017
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIVAndrea De Luca, Patrizia Lorenzini, Antonella Castagna, et al.
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2020
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patientsFrancesco Saladini, Alessia Giannini, Federica Giammarino, et al.
BMC Infectious Diseases|March 8, 2017
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyElena Raffetti, Francesco Donato, Salvatore Casari, et al.
The Journal of Antimicrobial Chemotherapy|December 23, 2019
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
The Lancet. HIV|October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trialFranco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Open Forum Infectious Diseases|May 22, 2026
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA CohortAlessandra Vergori, Adriana Cervo, Ashley Roen, et al.
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
Pageof 15